Osthol ameliorates obesity-associated lipid metabolic disorders by inhibiting ADRA1D-dependent Th17 cell differentiation
8.5
来源：
Nature
关键字：
mRNA
发布时间：
2025-10-21 23:51
摘要：
Osthol (OST) is shown to ameliorate obesity-related metabolic disorders by inhibiting Th17 cell differentiation through ADRA1D signaling. In HFD-induced obesity models, OST reduced body weight, serum lipids, and liver damage, while enhancing anti-inflammatory cytokines. The study provides insights into OST's mechanism, suggesting its potential as a therapeutic target for metabolic diseases, emphasizing the importance of ADRA1D in regulating inflammation and lipid metabolism.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
OST significantly reduced HFD-induced weight gain and improved metabolic parameters.
The study elucidated the mechanism of OST's action on Th17 cell differentiation via ADRA1D.
OST's effects were validated in both in vitro and in vivo models.
真实性检查
否
AI评分总结
Osthol (OST) is shown to ameliorate obesity-related metabolic disorders by inhibiting Th17 cell differentiation through ADRA1D signaling. In HFD-induced obesity models, OST reduced body weight, serum lipids, and liver damage, while enhancing anti-inflammatory cytokines. The study provides insights into OST's mechanism, suggesting its potential as a therapeutic target for metabolic diseases, emphasizing the importance of ADRA1D in regulating inflammation and lipid metabolism.